Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Scott Boerner

3PUBLICATIONS

38CO-AUTHORS

Molecular targetsImmunogenetics (incl. genetic immunology)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Jun 26, 2024

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).

Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro

|Jun 28, 2023

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.

Michael Cecchini, Zenta Walther, Wei Wei

|Mar 27, 2023

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma.

Kristina Fanucci, Mary Jo Pilat, Derek Shyr

Pageof 1

Frequent Collaborators

3 joint publications

Patricia LoRusso

2 joint publications

Mary Jo Pilat

2 joint publications

Diane E Durecki

1 joint publications

Michael Cecchini

1 joint publications

Zenta Walther

1 joint publications

Wei Wei

1 joint publications

Navid Hafez

1 joint publications

Joseph P Eder

1 joint publications

Kurt A Schalper

1 joint publications

Alice P Chen

Frequent Collaborators

3 joint publications

Patricia LoRusso

2 joint publications

Mary Jo Pilat

2 joint publications

Diane E Durecki

1 joint publications

Michael Cecchini

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on : Feb 12, 2017

Evaluating <em>In Vitro</em> DNA Damage Using Comet Assay

Evaluating <em>In Vitro</em> DNA Damage Using Comet Assay

Published on : Oct 11, 2017

See more related videos

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on : Feb 12, 2017

Evaluating <em>In Vitro</em> DNA Damage Using Comet Assay

Evaluating <em>In Vitro</em> DNA Damage Using Comet Assay

Published on : Oct 11, 2017

See more related videos